UBS Securities Upped Biogen Idec (NDAQ:BIIB) Rating; Empire District Electric Co (EDE)’s Sentiment Is 0.76

June 19, 2017 - By Nellie Frank

Among 9 analysts covering Biogen Idec Inc. (NDAQ:BIIB), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Biogen Idec Inc. has $345 highest and $278 lowest target. $307’s average target is 17.18% above currents $261.99 stock price. Biogen Idec Inc. had 12 analyst reports since March 2, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, April 26 by Cowen & Co. The stock of Biogen Inc (NASDAQ:BIIB) has “Buy” rating given on Thursday, March 2 by Instinet. As per Thursday, March 30, the company rating was maintained by Robert W. Baird. Mizuho maintained the shares of BIIB in report on Wednesday, April 19 with “Hold” rating. Robert W. Baird maintained Biogen Inc (NASDAQ:BIIB) rating on Wednesday, April 19. Robert W. Baird has “Neutral” rating and $290 target. Bernstein maintained it with “Outperform” rating and $310 target in Wednesday, April 26 report. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Thursday, March 16 report. The firm has “Mkt Perform” rating given on Thursday, March 16 by Leerink Swann. The firm has “Hold” rating by Mizuho given on Friday, April 28.

The Empire District Electric Company is a regulated utility company. The company has market cap of $1.50 billion. The Firm is engaged in the generation, purchase, transmission, distribution and sale of electricity. It currently has negative earnings. It provides services with in Missouri, Kansas, Oklahoma and Arkansas.

Since January 9, 2017, it had 2 insider buys, and 5 insider sales for $4.84 million activity. Vounatsos Michel also bought $380,425 worth of Biogen Inc (NASDAQ:BIIB) shares. 5,450 shares were sold by PANGIA ROBERT W, worth $1.61 million. Shares for $542,952 were sold by Sandrock Alfred. Posner Brian S also sold $277,840 worth of Biogen Inc (NASDAQ:BIIB) on Friday, June 9. The insider Clancy Paul J sold $2.88M.

About 999,696 shares traded. Biogen Inc (NDAQ:BIIB) has risen 4.94% since June 19, 2016 and is uptrending. It has underperformed by 11.76% the S&P500.

Analysts await Biogen Inc (NASDAQ:BIIB) to report earnings on July, 20. They expect $4.83 earnings per share, down 7.29% or $0.38 from last year’s $5.21 per share. BIIB’s profit will be $1.01B for 13.57 P/E if the $4.83 EPS becomes a reality. After $5.20 actual earnings per share reported by Biogen Inc for the previous quarter, Wall Street now forecasts -7.12% negative EPS growth.

Investors sentiment decreased to 0.92 in 2016 Q4. Its down 0.08, from 1 in 2016Q3. It dropped, as 90 investors sold Biogen Inc shares while 341 reduced holdings. 93 funds opened positions while 304 raised stakes. 183.23 million shares or 1.51% less from 186.04 million shares in 2016Q3 were reported. Gardner Lewis Asset Mgmt Limited Partnership holds 0.18% of its portfolio in Biogen Inc (NASDAQ:BIIB) for 8,355 shares. Airain Ltd, Guernsey-based fund reported 35,834 shares. Umb Bancorporation N A Mo has invested 0.01% in Biogen Inc (NASDAQ:BIIB). Lipe Dalton holds 16,982 shares or 3.43% of its portfolio. Factory Mutual Insurance holds 0.36% or 104,700 shares. Creative Planning owns 43,630 shares or 0.08% of their US portfolio. Tudor Investment Et Al holds 0.06% of its portfolio in Biogen Inc (NASDAQ:BIIB) for 7,815 shares. Guggenheim Lc reported 0.27% in Biogen Inc (NASDAQ:BIIB). Bb&T reported 5,650 shares. Columbia Asset Management stated it has 630 shares or 0.06% of all its holdings. Metropolitan Life Ins Com Ny reported 117,582 shares. Prudential Public Limited Company owns 0.05% invested in Biogen Inc (NASDAQ:BIIB) for 58,574 shares. Royal National Bank & Trust Of Canada, a Ontario – Canada-based fund reported 480,435 shares. State Of Wisconsin Invest Board reported 252,657 shares. Whittier Com stated it has 17,230 shares.

Biogen Inc. is a biopharmaceutical company. The company has market cap of $54.86 billion. The Firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. It has a 16.43 P/E ratio. The Firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis , FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: